Concord Biotech

Concord Biotech reported a revenue of ₹278 crores in Q3 FY26, marking a 14% year-on-year growth. However, for the nine-month period, revenues declined by 5% to ₹729 crores, primarily due to challenges faced in H1 FY26. API revenues were a strong driver, growing 24% YoY to ₹219 crores in Q3, while formulation revenues saw a decline to ₹58 crores from ₹68 crores in the prior year.

The company's reported EBITDA for Q3 FY26 stood at ₹99 crores, resulting in an EBITDA margin of 35.6%. Management clarified that excluding start-up costs associated with the new injectable facility and the US subsidiary, Stellon Biotech, core EBITDA margins remained robust at 40% for both Q3 and the nine-month period. These temporary impacts are expected to normalize as the injectable business scales up in the coming quarters.

Concord Biotech outlined a long-term growth strategy targeting a 25% CAGR, driven by injectables and CDMO opportunities, each contributing an estimated 6% to growth. The injectable facility, now WHO GMP certified, has a peak revenue potential of ₹600 crores and will initially focus on the domestic market before expanding to emerging markets. The company is also actively pursuing CDMO partnerships and leveraging its US subsidiary, Stellon Biotech, for direct market presence and in-licensing opportunities.

The first half of FY26 was impacted by several external factors, including uncertainties from US tariff dynamics, a delay in CDSCO written confirmation for European market sales, and the deferment of tender-based supplies to the Middle East due to geopolitical tensions. While CDSCO approval was received in November and tariff concerns for generics were clarified, the Middle East situation remains under close monitoring. These headwinds were characterized as timing-related rather than structural.

Concord Biotech maintains a zero-debt position, with cash and cash equivalents totaling ₹350 crores as of December 31, 2025. The company's annual capex plan for FY26 and beyond is in the range of ₹100-150 crores, which is a blend of maintenance (₹30-40 crores) and investments in newer growth projects. This disciplined capital allocation supports its expansion initiatives without incurring debt.

The company completed DMFs for Nystatin and Voclosporin last year and plans to launch two new anti-infective products in the current year, targeting niche segments with limited competition. Its non-immunosuppressant portfolio, including anti-infectives, antifungals, and oncology products, follows the same strategy of focusing on complex products with limited competition. API growth is primarily volume-driven, with strategic discounts sometimes offered for larger growth.

For Q3 FY26, Concord Biotech reported varying capacity utilization rates across its units. Unit 1 operated at 81% utilization, while Unit 3 was at 40% and Unit 2 at 27%. These figures provide insight into the operational efficiency and available headroom for future growth across its manufacturing facilities.